Tenaya Therapeutics (TNYA) Total Current Liabilities (2020 - 2026)

Tenaya Therapeutics has reported Total Current Liabilities for 7 years, with the latest figure at $16.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 18.58% year-over-year to $16.8 million; the trailing twelve-month figure through Mar 2026 stood at $16.8 million (up 18.58% YoY), and the FY2025 full-year result was $15.4 million, down 3.37% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $16.8 million, up from $15.4 million in the prior quarter.
• The five-year high for Total Current Liabilities was $24.2 million in Q4 2022, with the low at $12.7 million in Q2 2025.
• Average Total Current Liabilities over 5 years is $17.8 million, with a median of $17.7 million recorded in 2022.
• Year-over-year, Total Current Liabilities soared 91.23% in 2022 and slipped 29.73% in 2024.
• Tracing TNYA's Total Current Liabilities over 5 years: stood at $24.2 million in 2022, then decreased by 6.25% to $22.7 million in 2023, then fell by 29.73% to $16.0 million in 2024, then dropped by 3.37% to $15.4 million in 2025, then grew by 8.71% to $16.8 million in 2026.
• The last three Total Current Liabilities figures came in at $16.8 million (Q1 2026), $15.4 million (Q4 2025), and $13.2 million (Q3 2025), per Business Quant data.

Peer Comparison